# TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

> **NCT02927964** · PHASE1,PHASE2 · COMPLETED · sponsor: **Robert Lowsky** · enrollment: 21 (actual)

## Conditions studied

- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **RADIATION:** Radiation Therapy
- **DRUG:** TLR9 Agonist SD-101

## Key facts

- **NCT ID:** NCT02927964
- **Lead sponsor:** Robert Lowsky
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-07
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927964, "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02927964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*